Apologies if this New York Times article has been shared already - may be of interest to some.
Link to Article
Pity the New York Times can't use google or maybe they'd have included Rem in their approved treatments paragraph along with HSCT and maybe raised the profile a bit. Also happy for MSB treatment to proceed as 'precursor' (MPCs) or Stromal given the politically fraught nature of recent changes but ultimately the treatment(s) will speak for themselves.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
0.035(2.22%) |
Mkt cap ! $2.057B | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.63 | $1.58 | $6.778M | 4.238M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2342 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 40395 | 3 |
View Market Depth
| Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |